Abstract #0472
Exploring the inherent CEST MRI signal of anticancer drug gemcitabine
Yuguo Li 1,2 , Kannie Chan 1,2 , peter van Zijl 1,2 , Bert Vogelstein 3 , Michael McMahon 1,2 , Shibin Zhou 3 , and Guanshu Liu 1,2
1
Radiology, Johns Hopkins University School
of Medicine, Baltimore, MD, United States,
2
FM
Kirby center, Kennedy Krieger Institute, Baltimore, MD,
United States,
3
Ludwig
Center, Howard Hughes Medical Institute and Sidney
Kimmel Cancer Center, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
Non-invasive tracking of drug delivery is of great
clinical interest. Herein, we explored a direct way to
track liposome mediated delivery of gemcitabine, a
first-line drug for treating pancreatic cancer. We show
that this can be achieved using its inherent Chemical
Exchange Saturation Transfer (CEST) MRI signal at 2.1
and 1.0 ppm originating from the exchangeable amino and
hydroxyl protons, respectively. Unlike traditional
approaches, the CEST MRI detection doesnt require the
use of extra contrast agents, and is able to directly
convert the gemcitabine-loaded nanoparticle drug
delivery system into a theranostic system.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
